TScan Therapeutics, Inc.
Clinical trials sponsored by TScan Therapeutics, Inc., explained in plain language.
A clinical-stage biotech developing T-cell receptor therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Custom immune cells take on multiple cancers in early trial Results expected Dec 2026 (estimated)
-
Supercharged donor cells aim to stop leukemia return after transplant
Cure Recruiting nowThis study tests a new approach to prevent leukemia from coming back after a stem cell transplant. It uses donor T cells that have been engineered to recognize and attack a specific target (HA-2) on leukemia cells. The trial enrolls adults with acute myeloid leukemia (AML) or mye…
Phase 3 • Sponsor: TScan Therapeutics, Inc. • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
Supercharged donor cells aim to stop blood cancer relapse after transplant
Disease control Recruiting nowThis early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely reduce the risk of cancer returning after a stem cell transplant. About 75 adults with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphoblastic leukemia w…
Phase 1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
15-Year study launches to monitor safety of experimental TCR-T therapy
Knowledge-focused Recruiting nowThis study follows 1,000 people who previously received an experimental cell therapy (TSC-100 or TSC-101) for blood cancers like leukemia. Researchers will track side effects and survival for up to 15 years to see if the treatment remains safe and effective over time. No new trea…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:52 UTC